Inhibitory effects of NSAID-conjugated SN-38 on the viability of A549 Non-small cell lung cancer cells.

Biochem Biophys Rep

Department of Bioconvergence System, Graduate School, and BioChip Research Center, Hoseo University, Asan, 336-795, South Korea.

Published: September 2023

The goal of this paper was to look into the anti-tumor mechanism of Non-Steroidal Anti-Inflammatory Drug (NSAID)-conjugated SN-38 Prodrug in A549 lung cancer cells. We found that Indomethacine-SN-38 (IndoSN-38) and Naproxen-SN-38(NaproSN-38) as a theranostic prodrug targeting cyclooxygenase-2(COX-2) in cancer cells inhibited A549 cell viability in a dose-dependent fashion. IndoSN-38 and NaproSN-38 inhibited A549 cell viability in a dose-dependent fashion. The suppression of A549 cell viability was due to induction of the cell apoptosis by enhancing the activities of Caspase 3 and Caspase 8. The cell cycle arrest of sub-G1 was found in the cells treated with IndoSN-38 or NaproSN-38. Collectively, these data suggested that the anti-proliferative activities of the NSAID-conjugated SN-38 prodrugs were due to promotion of cell death and arresting the cell cycle which was similar with those of SN-38.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374863PMC
http://dx.doi.org/10.1016/j.bbrep.2023.101517DOI Listing

Publication Analysis

Top Keywords

nsaid-conjugated sn-38
12
cancer cells
12
a549 cell viability
12
lung cancer
8
inhibited a549 cell
8
viability dose-dependent
8
dose-dependent fashion
8
indosn-38 naprosn-38
8
cell cycle
8
cell
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!